GlassScriptPhysician profile
Ioana Moldovan
NPI 1740201557
$128,317.73
in general payments reported to CMS, 2019-2025
39 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $18K · 2021: $10K · 2022: $14K · 2023: $11K · 2024: $21K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $14K · Travel and Lodging: $5,572 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,176.44 |
| Food and Beverage | $14,470.41 |
| Travel and Lodging | $5,571.85 |
| Education | $373.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69,854.82 | 2019-2025 | Evenity, Otezla, Otezla |
| Horizon Therapeutics Plc | $22,896.66 | 2019-2023 | Krystexxa |
| Abbvie INC. | $16,943.85 | 2019-2025 | |
| Ucb, INC. | $3,709.95 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $2,238.66 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,715.54 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,620.06 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $1,447.42 | 2019-2025 | Benlysta |
| Celgene Corporation | $1,250.88 | 2019 | |
| Pfizer INC. | $965.36 | 2019-2025 | |
| Lilly USA, LLC | $964.42 | 2019-2025 | Taltz, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $961.67 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $655.23 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $633.65 | 2019-2025 | Orencia |
| Genentech USA, INC. | $380.87 | 2019-2024 | Actemra |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $241.63 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $230.38 | 2019-2022 | |
| Radius Health, INC. | $179.30 | 2019-2025 | Tymlos |
| Sobi, INC | $177.63 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.44 | 2019-2023 | Cyltezo |
| Genzyme Corporation | $155.40 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $125.48 | 2019 | |
| Corcept Therapeutics | $124.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $91.28 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $77.56 | 2023-2024 | Strensiq |
| Shire North American Group INC | $76.41 | 2019 | |
| Sandoz INC. | $70.63 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $59.64 | 2024 | Idacio |
| Kyowa Kirin, INC. | $44.83 | 2023-2025 | Crysvita |
| Octapharma USA, INC. | $42.08 | 2024 | Octagam Immune Globulin (Human), Panzyga |
| Gilead Sciences, INC. | $37.98 | 2024 | |
| Scilex Pharmaceuticals INC. | $33.11 | 2024 | |
| Celltrion USA INC. | $29.52 | 2025 | Vegzelma |
| Medexus Pharma, INC. | $28.82 | 2019 | |
| Tonix Medicines, INC. | $25.48 | 2025 | Tonmya |
| Bioventus LLC | $19.24 | 2022 | |
| Alvogen INC | $18.48 | 2024 | Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $16.37 | 2024 | |
| Mylan Institutional INC. | $13.05 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ioana Moldovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.